NCT02640092已完成1 期
Longitudinal Evaluation of [18F]GTP1 as a PET Radioligand for Imaging Tau in the Brain of Patients With Prodromal, Mild, and Moderate Alzheimer's Disease Compared to Healthy Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 72
- 试验地点
- 16
- 主要终点
- Change in Standardized Uptake Value Ratio (SUVR) as Measured by [18F]GTP1
研究概览
简要总结
This is an open-label, longitudinal observational study evaluating the imaging characteristics of the tau positron-emission tomography (PET) radioligand [18F] Genentech Tau Probe 1 (GTP1) in the brain of participants with prodromal, mild, and moderate Alzheimer's disease (AD) compared to healthy participants. The overall goal of this protocol is to evaluate the longitudinal change in tau burden using [18F]GTP1, a tau targeted radiopharmaceutical.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 50 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •For All Participants:
- •Availability of a study partner who, in the investigator's judgment, has frequent and sufficient contact with the participant and is able to provide accurate information regarding the participant's cognitive and functional abilities, agrees to accompany the participant and provide information at visits
- •For Healthy Participants:
- •Healthy with no clinically relevant finding on physical examination at screening and upon reporting for the Baseline [18F]GTP1 imaging visit
- •Have no cognitive complaint
- •Have a Clinical Dementia Rating Scale (CDR) global score = 0
- •Have a Mini-Mental State Examination (MMSE) score of 28-30
- •For Participants With a Diagnosis of AD:
- •Participants with mild or moderate AD must meet National Institute on Aging - Alzheimer's Association (NIA-AA) core clinical criteria for probable AD dementia, with an amnestic presentation
- •Participants with prodromal AD must meet NIA-AA core clinical criteria for mild cognitive impairment (MCI)
- •Have screening [18F]florbetapir PET imaging demonstrating amyloid binding based on qualitative visual read
- •A brain MRI consistent with a diagnosis of AD, with no evidence of non-AD disease to account for dementia or MRI exclusion criteria
- •Medications taken for symptomatic treatment of AD must remain stable for at least 30 days prior to screening visit
- •Satisfy one of the following subgroups: Approximately 20 prodromal AD (MMSE 24-30, CDR = 0.5); Approximately 20 mild AD (MMSE 22-30, CDR = 0.5 or 1); Approximately 20 moderate AD (MMSE 16-21, CDR = 0.5 or 1 or 2)
排除标准
- •Current or prior history of any drug or alcohol abuse
- •Participants with any significant psychiatric, neurological, or unstable medical disorder expected to interfere with the study
- •Participants unable to undergo MRI and PET scan
- •For participants contributing CSF samples, any contraindication to lumbar puncture
- •Prior participation in other research protocols or clinical care in the last year such a radiation exposure combined with that from the present study exceeds an effective dose of 50 millisievert (mSV), the allowable annual limit for research participants as stipulated by the Food and Drug Administration (FDA)
研究组 & 干预措施
[18F]GTP1
Experimental
Participants will complete [18F]GTP1 PET imaging at four time points: Baseline, 6 months, 12 months and 18 months. For each [18F]GTP1 imaging session, the following procedure will be performed: a catheter will be placed for intravenous (IV) administration of [18F]GTP1. Participants will receive an IV bolus injection of up to 370 megabecquerel (MBq) (10 millicurie [mCi]) of [18F]GTP1.
干预措施: [18F]GTP1 (Drug)
结局指标
主要结局
Change in Standardized Uptake Value Ratio (SUVR) as Measured by [18F]GTP1
时间窗: From Baseline to 18 months
次要结局
- Correlation Coefficient Between Change in SUVR (as Measured by [18F]GTP1) and Change in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog)13(From Baseline to 18 months)
- Percentage of Participants With Adverse Events (AEs)(From Baseline to 18 months)
- Correlation Coefficient Between Change in SUVR (as Measured by [18F]GTP1) and Change in Volumetric Magnetic Resonance Imaging (MRI) Measures(From Baseline to 18 months)
- Test-Retest Variability Based on [18F]GTP1 PET Scans(From date of test scan to 7-21 days after test scan)
- Correlation Coefficient Between Change in SUVR (as Measured by [18F]GTP1) and Change in Cerebrospinal Fluid (CSF) Markers(From Baseline to 18 months)
研究者
研究点 (16)
Loading locations...
相似试验
已完成
2 期
Diagnostic Validity of [18F]GP1 PET for Diagnosing Acute Deep Vein ThrombosisVenous ThrombosisNCT04156230Dae Hyuk Moon52
已完成
1 期
Practical evaluation of PET studies with [18F]-GE180, [18F]-FDOPA and [18F]-FLT for a future clinical trial of iPSC-based cell therapy in Parkinson's diseaseneuroinflammatory disorder, Parkinson's disease, Brain tumorJPRN-UMIN000030084Kyoto University12
进行中（未招募）
1 期
Study to see if new research scans can show how treatment affects the blood supply to kidney cancersPrimary and metastatic cancer. The active substance is a diagnostic agent that identifies angiogenesis associated with tumour growth.MedDRA version: 14.1 Level: PT Classification code 10050018 Term: Renal cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1 Level: PT Classification code 10038389 Term: Renal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-002833-20-GBOxford University Hospitals NHS Trust10
终止
1 期
PET/CT Imaging Study of the Safety and Diagnostic Performance of [68Ga]RM2 in Patients With Primary Prostate CancerProstate CancerNCT02483884Life Molecular Imaging SA30
尚未招募
不适用
[18F]PEG-Folate PET-CT imaging for monitoring of therapy response in Rheumatoid Arthritis patientsRheumatoid ArthritisNL-OMON26919GSK10